drugset
Drugs / GSK 692342
last change Nov 2018 re-read 3 minutes ago

GSK 692342

also known as 692342

Vaccine

Developed for
tuberculosis
Investigated by
GlaxoSmithKline · Aeras

Trials 4

today NCT01755598 · Ph 2 NCT01669096 · Ph 2 NCT01424501 · Ph 2 NCT00397943 · Ph 2
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01755598 Aug 2014 → Nov 2018 tuberculosis GlaxoSmithKline Completed Met primary
Phase 2 NCT01669096 Aug → Dec 2012 tuberculosis GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT01424501 Nov 2011 → Apr 2014 tuberculosis GlaxoSmithKline Terminated No outcome recorded
Phase 2 NCT00397943 Nov 2006 → Dec 2009 tuberculosis GlaxoSmithKline Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as GSK 692342 “Efficacy of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 Against TB Disease, in Adults Living in a TB Endemic Region” NCT01755598 ↗
4

“tuberculosis vaccine GSK692342” NCT00397943 ↗

NCT01669096 ↗

NCT01424501 ↗

NCT01755598 ↗
Known as 692342 “GSK's candidate Mycobacterium tuberculosis vaccine 692342” NCT00397943 ↗
Modality Vaccine “Tuberculosis vaccine GSK692342” NCT00397943 ↗
Route Intramuscular “administered intramuscularly” NCT01669096 ↗